The aforementioned results suggested that the SHP-1 agonist SC-43 may exert its anti-pulmonary fibrosis activities, at least partially, by transcriptionally reducing the expression of CSF1R in macrophages, which leads to the apoptosis of macrophages and reshaping of the immunofibrotic niche. Here, PTPN6 is linked to pulmonary fibrosis.